Central Asia has moved from a curiosity to a genuine opportunity in the last 24 months. Reforms in Uzbekistan, rising per-capita income in Kazakhstan, and a wave of pharmacy chain consolidation across the region are pulling in Indian wellness and nutraceutical brands at pace. What used to be a market you 'kept an eye on' is now one where late entrants will find the good shelves already taken.
Uzbekistan is the standout story. President Mirziyoyev's reforms since 2017 have simplified currency conversion, cut import tariffs on health products, and dramatically reduced the friction of foreign brand registration. Combined with a population of 36 million — young, urbanising, and increasingly health-conscious — the market has become the fastest-growing destination for Indian pharma and nutra in the CIS.
Kazakhstan is the premium play. Per-capita income is 3–4x Uzbekistan's, modern trade penetration is high, and consumers are willing to pay for internationally-recognised brands. It is also a gateway to the Eurasian Economic Union (EAEU) — a product registered in Kazakhstan can, with additional filings, be sold tariff-free in Russia, Belarus, Kyrgyzstan and Armenia. That is a 200-million-consumer bloc accessible from a single beachhead.
Registration timelines are shorter than the GCC and considerably shorter than Africa. Uzbekistan can complete nutraceutical registration in 4–6 months; Kazakhstan in 6–9 months. Distributor economics are attractive — margins from importer to shelf typically total 45–55%, similar to India's own trade but with much less clutter and pricing pressure.
The cultural fit is real. Ayurveda-anchored positioning has genuine resonance across Central Asia in a way that surprises first-time entrants. Herbal supplements, immunity products, joint-care and women's wellness categories all outperform baseline nutra growth rates. Positioning should lead with heritage and natural sourcing, not Western-style clinical claims, which the market discounts.
The right entry sequence is deliberate. Enter Uzbekistan first — larger population, faster registration, lower cost of experimentation, and forgiving of new brands. Use 12–18 months to build a repeatable playbook: distributor onboarding, pharmacy chain listing, MR training in Russian and Uzbek, digital-plus-pharmacy hybrid marketing. Then enter Kazakhstan for premium positioning and margin, using your Uzbekistan track record as credibility. Finally, radiate outward into Kyrgyzstan, Tajikistan and Turkmenistan through regional partners already handling your goods.
Language matters more than most exporters expect. Product literature, packaging, MR detailing materials and digital creative should all be produced in Russian at minimum, with Uzbek and Kazakh translations for consumer-facing communication. Investing in a proper localisation partner (not machine translation) pays for itself in the first quarter.
One structural warning: payment cycles in Central Asia are longer than the GCC and comparable to Africa. Advance or LC for the first 12 months, moving to 45–60 day credit only after a full year of clean history. Currency volatility (particularly the som and tenge) should be hedged into your USD price list with quarterly review clauses.